Comprehensive Analysis of Hypermutation in Human CancerBrittany Campbell, Melyssa Aronson, Tanner M. Johanns et al.|Cell|2017Cited by 795
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trialBirgit Geoerger, Navin Pinto, Hyoung Jin Kang et al.|The Lancet Oncology|2019Cited by 341
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)Ankit Kansagra, Shahrukh K. Hashmi, Noelle V. Frey et al.|Bone Marrow Transplantation|2019Cited by 119
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular TherapyAnkit Kansagra, Shahrukh K. Hashmi, Noelle V. Frey et al.|Biology of Blood and Marrow Transplantation|2018Cited by 106
Opportunities and Challenges in Drug Development for Pediatric CancersTheodore W. Laetsch, Lucas Moreno, Steven G. DuBois et al.|Cancer Discovery|2020Cited by 70